Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,071.63 +1.08 (+0.02%) Dow
38,460.92 -42.77 (-0.11%) Nasdaq
15,712.75 +16.11 (+0.10%) Bitcoin USD
64,267.80 -2,155.81 (-3.25%) CMC Crypto 200
1,383.20 -40.90 (-2.87%)
Marizyme, Inc. (MRZM)
| Previous close | 0.0950 |
| Open | 0.0950 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0950 - 0.0950 |
| 52-week range | 0.0500 - 0.4100 |
| Volume | |
| Avg. volume | 3,537 |
| Market cap | 4.433M |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8600 |
| Earnings date | 15 May 2024 - 19 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireMarizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™. DuraGraft™ was granted a De Novo – FDA Clearance on October 4, 2023, from the U.S. Food and Drug Administration (FDA). DuraGraft™ is labeled for use as a vascular conduit sol
- GlobeNewswire
Marizyme CEO Delivers Business Update
JUPITER, FL, Oct. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the investing public from the Company’s Chief Executive Officer, David Barthel: “I am very pleased to bring you an update on the Company’s FDA Clearance for DuraGraft™ as well as Marizyme’s business priorities for 2024. “After our last business update on May 3, 2023, the Company has been focused on secur
